More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first ...

More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first immunotherapy against cancer. And it is still used today to treat ...

What Is BCG Treatment for Bladder Cancer? Bacillus Calmette-Guérin (BCG) is the main immunotherapy used to treat early-stage bladder cancer. Immunotherapy uses your immune system to fight cancer.

The treatment draws your body’s immune cells to your bladder. There, they’re activated by the BCG and begin to fight the cancer cells. Nogapendekin alfa inbakicept (Anktiva), a medication that ...

Several studies have shown increased PD-1 expression in bladder tumors after BCG treatment, supporting combination treatment with a PD(L)1 inhibitor. Sasanlimab demonstrated durable anti-tumor ...

Dr. Daniel P. Petrylak discusses the different types of bladder cancer and how treatment options may vary based on disease ...

With the data presented of 99% disease specific survival at 12 months and over 82% patients not requiring bladder removal, it is essential that these patients be provided this treatment option, ...

The CISTO study is the only going prospective study comparing radical cystectomy vs bladder-sparing options for high-grade NMIBC.

“We look forward to working with global regulatory authorities to potentially bring sasanlimab as an important new treatment ... and BCG combo therapy improves EFS in bladder cancer trial ...

BCG might be superior to sequential intravesical gemcitabine-docetaxel for reducing the risk of recurrence in patients with high-grade intermediate-risk NMIBC. Given the recent global shortage of ...

Cretostimogene is similar to BCG in terms of its intravesical ... with the goal of bringing bladder-sparing treatments that provide durable, efficacious, and safe outcomes to patients.